Diabetes and metabolic dysfunction in COPD

Respiratory Medicine: COPD Update

Volumn 5, Issue 3-4, 2009, Pages 67-74

  Archer, J R H ^a   Baker, E H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ACE inhibitors; Insulin resistance; Metabolic syndrome; Oral hypoglycaemics; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BUDESONIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN RECEPTOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

BORDERLINE HYPERTENSION; CACHEXIA; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSLIPIDEMIA; EXERCISE; FLUID RETENTION; FOLLOW UP; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; HYPOXIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LUNG FUNCTION; LUNG INFECTION; LUNG INJURY; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHYSIOLOGICAL STRESS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; VASCULAR DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 70849127297     PISSN: 17450454     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedu.2009.10.001     Document Type: Review

References (80)

1. World Health Organisation. International diabetes federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf
2. Donner H., Rau H., Walfish P., Braun J., Siegmund T., Finke R., et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 82 1 (1997) 143-146
3. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30 (2007) 753-759
4. Rolih C.A., and Ober K.P. The endocrine response to critical illness. Med Clin North Am 79 (1995) 211-224
5. McGuinness O.P. Defective glucose homeostasis during infection. Annu Rev Nutr 25 (2005) 9-35
6. Baker E.H., Janaway C.H., Philips B.J., Brennan A.L., Baines D.L., Wood D.M., et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61 (2006) 284-289
7. Chatila W.M., Thomashow B.M., Minai O.A., Criner G.J., and Make B.J. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008) 549-555
8. Mannino D.M., Thorn D., Swensen A., and Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32 (2008) 962-969
9. Rana J.S., Mittleman M.A., Sheikh J., Hu F.B., Manson J.E., Colditz G.A., et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 27 (2004) 2478-2484
10. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 34 (2001) 50s-59s
11. Eid A.A., Ionescu A.A., Nixon L.S., Lewis-Jenkins V., Matthews S.B., Griffiths T.L., et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 1414-1418
12. Hu F.B., Meigs J.B., Li T.Y., Rifai N., and Manson J.E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53 (2004) 693-700
13. Bolton C.E., Evans M., Ionescu A.A., Edwards S.M., Morris R.H., Dunseath G., et al. Insulin resistance and inflammation - a further systemic complication of COPD. COPD 4 (2007) 121-126
14. Grimble R.F. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5 (2002) 551-559
15. Liu L.S., Spelleken M., Rohrig K., Hauner H., and Eckel J. Tumour necrosis factor-alpha acutely inhibits insulin signaling in human adipocycyes - implication of the P80 tumor necrosis factor receptor. Diabetes 47 (1998) 515-522
16. Oltmanns K.M., Gehring H., Rudolf S., Schultes B., Rook S., Schweeiger U., et al. Hypoxia causes glucose intolerance in humans. Am J Respir Crit Care Med 169 (2004) 1231-1237
17. Hjalmarsen A., Aasebø U., Birkeland K., Sager G., and Jorde R. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 22 (1996) 37-42
18. Jakobsson P., and Jorfeldt L. Oxygen supplementation increases glucose tolerance during euglycaemic hyperinsulinaemic glucose clamp procedure in patients with severe COPD and chronic hypoxaemia. Clin Physiol Funct Imaging 26 (2006) 271-274
19. Wood-Baker R., Walters J., and Walters E.H. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir Med 101 (2007) 371-377
20. Canis R., Demirkok S.S., Osar Z., Balci H., and Can G. Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic obstructive pulmonary disease. Adv Ther 24 (2007) 560-570
21. Faul J.L., Wilson S.R., Chu J.W., Canfield J., and Kuschner W.G. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res 7 (2009) 14-20
22. Pauwels R.A., Löfdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med 340 (1999) 1948-1953
23. Chakrabarti B., Nagus R.M., Agarwal S., Lane S., and Calverley P. Hyperglycaemia as a predictor of outcome during non invasive ventilation in decompensated COPD. Thorax (2009) 10.1136/thx.2008.106989
24. Moretti M., Cilione C., Tampieri A., Fracchia C., Marchioni A., and Nava S. Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax 55 (2000) 819-825
25. Wouters E.F.M., Groenewegen K.H., Dentener M.A., and Vernooy J.H.J. Systemic inflammation in chronic obstructive pulmonary disease. The role of exacerbations. Proc Am Thorac Soc 4 (2007) 626-634
26. Adrogue H.J., Chap Z., Okuda Y., Michael L., Hartley C., Entman M., et al. Acidosis-induced glucose intolerance is not prevented by adrenergic blockade. Am J Physiol 255 (1988) E812-E823
27. Garcia-Aymerich J., Félez M.A., Escarrabill J., Marrades R.M., Morera J., Elosua R., et al. Physical activity and its determinants in severe chronic obstructive pulmonary disease. Med Sci Sports Exerc 36 (2004) 1667-1673
28. Crisafulli E., Costi S., Luppi F., Cirelli G., Cilione C., Coletti O., et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 63 (2008) 487-492
29. Loukides S., and Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 63 (1996) 170-173
30. Makarevich A.E., Valevich V.E., and Pochtavtsev A.U. Evaluation of pulmonary hypertension in COPD patients with diabetes. Adv Med Sci. 52 (2007) 265-272
31. Gudmundsson G., Gislason T., Lindberg E., Hallin R., Ulrik C.S., and Brondum E. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 7 (2006) 109
32. Weynand B., Jonckheere A., Frans A., and Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 66 (1999) 12-13
33. Strojeck K., Ziora D., Sroczynski J., and Oklek K. Pulmonary complications of type I (insulin-dependent) diabetic patients. Diabetologia 35 (1992) 1173-1176
34. Mori H., Okubo M., Okamura M., Yamane K., Kado S., Egusa G., et al. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Intern Med 31 (1992) 189-193
35. Hak E., Rovers M.M., Kuyvenhoven M.M., Schellevis F.G., and Verheij T.J. Incidence of GP-diagnosed respiratory tract infections according to age, gender and high-risk co-morbidity: the second Dutch national survey of general practice. Fam Pract 23 (2006) 291-294
36. Kornum J.B., Thomsen R.W., Riis A., Lervang H.H., Schneider H.C., and Sørensen H.T. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31 (2008) 1541-1545
37. Bouter K.P., Diepersloot R.J., van Romunde L.K., Uitslager R., Masurel N., Hoekstra J.B., et al. Effect of epidemic influenza on ketoacidosis, pneumonia and death in diabetes mellitus: a hospital register survey of 1976-1979 in The Netherlands. Diabetes Res Clin Pract 12 (1991) 61-68
38. Baker E.H., Wood D.M., Brennan A.L., Clark N., Baines D.L., and Philips B.J. Hyperglycaemia and Pulmonary Infection. Proc Nutr Soc 65 (2006) 227-235
39. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 (2002) 2067-2072
40. Martinez-Llorens J.M., Orozco-Levi M., Masdeu M.J., Coronell C., Ramirez-Sarmiento A., Sanjuas C., et al. Global muscle dysfunction and exacerbation of COPD: a cohort study. Med Clin (Barc) 122 (2004) 521-527
41. Vanhorebeek I., De V.R., Mesotten D., Wouters P.J., De Wolf-Peeters C., and Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 365 (2005) 53-59
42. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32 (2009) S13-S61
43. 1. The lung health study. JAMA 272 (1994) 1497-1505
44. Anthonisen N.R., Skeans M.A., and Wiase R.A. The effects of a smoking cessation intervention on 14.5-year mortality: a randomised clincial trial. Ann Intern Med 142 (2005) 233-239
45. Tonstad S. Cigarette smoking, smoking cessation, and diabetes. Diab Res Clin Pract 10 (2009) 1016-1026
46. Will J.C., Galuska D.A., Ford E.S., Mokdad F.A., and Calle E.E. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol 30 (2001) 540-546
47. NICE guidance on Type 2 diabetes. The management of type 2 diabetes. Last accessed (May 2009). http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.doc Issue date
48. Rachmani R., Slavachevski I., Levi Z., Zadok B., Kedar Y., and Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 13 (2002) 428
49. Vermeeren M.A., Wouters E.F., Nelissen L.H., van Lier A., Hofman Z., and Schols A.M. Acute effects of different nutritional supplements on symptoms and functional capacity in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 73 (2001) 295-301
50. Isoda K., Young J.L., Zirlik A., MacFarlane L.A., Tsuboi N., Gerdes N., et al. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler Thromb Biol 26 (2006) 611-617
51. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 24 (2008) 14-26
52. Dandona P., Mohanty P., Chaudhuri A., Garg R., and Aljada A. Insulin infusion in acute illness. J Clin Invest 15 (2005) 2069-2072
53. Vermeeren M.A., Wouters E.F., Geraerts-Keeris A.J., and Schols A.M. Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. Clin Nutr 23 (2004) 1184-1192
54. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
55. Van den Berghe G., Wilmer A., Hermans G., Meersseman W., Wouters P.J., Milants I., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006) 449-461
56. Finfer S., Chittock D.R., Su S.Y., Blair D., Foster D., Dhingra V., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 (2009) 1283-1297
57. Griesdale D.E., de Souza R.J., van Dam R.M., Heyland D.K., Cook D.J., Malhotra A., et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180 (2009) 821-827
58. Hansen T.K., Thiel S., Wouters P.J., Christiansen J.S., and Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88 (2003) 1082-1088
59. Hemmila M.R., Taddonio M.A., Arbabi S., Maggio P.M., and Wahl W.L. Intensive insulin therapy is associated with reduced infectious complications in burn patients. Surgery 144 (2008) 629-637
60. Ellger B., Richir M.C., Van Leeuwen P.A., Debaveye Y., Langouche L., Vanhorebeek I., et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 149 (2008) 3148-3157
61. Bellomo R., and Egi M. What is a NICE-SUGAR for patients in the intensive care unit?. Mayo Clin Proc 84 (2009) 400-402
62. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
63. Marquis K., Maltais F., Duguay V., Bezeau A.M., LeBlanc P., Jobin J., et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 25 (2005) 226-234
64. Watz H, Waschki B, Kirsten A, Müller KC, Kretschmar G, Meyer T et-al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009 Jun [Epub ahead of print].
65. Franssen F.M., O'Donnell D.E., Goossens G.H., Blaak E.E., and Schols A.M. Obesity and the lung: 5. Obesity and COPD. Thorax 63 (2008) 1110-1117
66. Scols A.M.W.J., Soeters P.B., Dingemans A.M.C., Mostert R., Frantzen P.J., and Wouters E.F. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 147 (1993) 1151-1156
67. Martyn J.A., Kaneki M., and Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 109 (2008) 137-148
68. Poulain M., Doucet M., Major G.C., Drapeau V., Sériès F., Boulet L.P., et al. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 174 (2006) 1293-1299
69. Williams K.V., Bertoldo A., Kinahan P., Cobelli C., and Kelley D.E. Weight loss-induced plasticity of glucose transport and phosphorylation in the insulin resistance of obesity and type 2 diabetes. Diabetes 52 (2003) 1619-1626
70. NICE guidance on obesity management in adults (quick reference guide). http://www.nice.org.uk/nicemedia/pdf/CG43quickrefguide2.pdf
71. de Lucas-Ramos P., Izquierdo-Alonso J.L., Rodríguez-González Moro J.M., Bellón-Cano J.M., Ancochea-Bermúdez J., Calle-Rubio M., et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Arch Bronconeumol 44 (2008) 233-238
72. Janda S., Park K., Fitzgerald J.M., Etminan M., and Swiston J. Statins in COPD: a systematic review. Chest (2009 Apr 17) [Epub ahead of print]
73. Mortensen E.M., Copeland L.A., Pugh M.J., Restrepo M.I., de Molina R.M., Nakashima B., et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 10 (2009) 45
74. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., and Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47 (2006) 2554-2560
75. Makhsida N., Shah J., and Yan G. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834
76. Basaria A., and Dobs A.S. Testosterone making an entry into the cardiometabolic world. Circulation 116 (2007) 2658-2661
77. Van Vliet M., Spruit M.A., Verleden G., Kasran A., Herck E.V., Pitta F., et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 1105-1111
78. Isidori A.M., Giannetta E., Greco E.A., Gianfrilli D., Bonifacio V., Isidori A., et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 63 (2005) 280-293
79. Svartberg J., Aasebø U., Hjalmarsen A., Sundsfjord J., and Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 98 (2004) 906-913
80. Casaburi R., Bhasin S., Cosentino L., Porszasz J., Somfay A., Lewis M.I., et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 870-878